RU2019126746A3 - - Google Patents

Download PDF

Info

Publication number
RU2019126746A3
RU2019126746A3 RU2019126746A RU2019126746A RU2019126746A3 RU 2019126746 A3 RU2019126746 A3 RU 2019126746A3 RU 2019126746 A RU2019126746 A RU 2019126746A RU 2019126746 A RU2019126746 A RU 2019126746A RU 2019126746 A3 RU2019126746 A3 RU 2019126746A3
Authority
RU
Russia
Application number
RU2019126746A
Other languages
Russian (ru)
Other versions
RU2019126746A (ru
RU2769317C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900385A external-priority patent/AU2017900385A0/en
Application filed filed Critical
Publication of RU2019126746A publication Critical patent/RU2019126746A/ru
Publication of RU2019126746A3 publication Critical patent/RU2019126746A3/ru
Application granted granted Critical
Publication of RU2769317C2 publication Critical patent/RU2769317C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019126746A 2017-02-08 2018-02-07 Способы лечения гриппа RU2769317C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900385A AU2017900385A0 (en) 2017-02-08 Methods of treating influenza
AU2017900385 2017-02-08
PCT/AU2018/050085 WO2018145148A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Publications (3)

Publication Number Publication Date
RU2019126746A RU2019126746A (ru) 2021-03-09
RU2019126746A3 true RU2019126746A3 (enExample) 2021-05-28
RU2769317C2 RU2769317C2 (ru) 2022-03-30

Family

ID=63106827

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019126746A RU2769317C2 (ru) 2017-02-08 2018-02-07 Способы лечения гриппа

Country Status (13)

Country Link
US (1) US10918623B2 (enExample)
EP (1) EP3579833B1 (enExample)
JP (1) JP7019727B2 (enExample)
KR (1) KR102607599B1 (enExample)
CN (1) CN110325187B (enExample)
AU (1) AU2018218179B2 (enExample)
BR (1) BR112019016316A2 (enExample)
CA (1) CA3052503A1 (enExample)
ES (1) ES2910136T3 (enExample)
MX (1) MX387115B (enExample)
RU (1) RU2769317C2 (enExample)
SG (1) SG11201907034PA (enExample)
WO (1) WO2018145148A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
BR122020020217B1 (pt) 2015-09-16 2021-08-17 Gilead Sciences, Inc Uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por arenaviridae
EP4331677A3 (en) 2017-03-14 2024-05-29 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CA3178212A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
PL3651734T3 (pl) 2017-07-11 2025-03-31 Gilead Sciences, Inc. Kompozycje zawierające inhibitor polimerazy rna i cyklodekstrynę do leczenia infekcji wirusowych
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202532084A (zh) 2020-05-29 2025-08-16 美商基利科學股份有限公司 瑞德西韋之治療方法
WO2021262826A2 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
CN116323630A (zh) 2020-08-24 2023-06-23 吉利德科学公司 磷脂化合物及其用途
PT4204421T (pt) 2020-08-27 2024-06-25 Gilead Sciences Inc Compostos e métodos para o tratamento de infeções virais
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
US12427150B2 (en) 2021-05-26 2025-09-30 Gilead Sciences, Inc. Phospholipid formulations of 1′-cyano substituted carba-nucleoside analogs
KR20240049311A (ko) 2021-08-18 2024-04-16 길리애드 사이언시즈, 인코포레이티드 인지질 화합물 및 이의 제조 및 사용 방법
WO2023092180A1 (en) * 2021-11-24 2023-06-01 Biotron Limited Methods of treating sars-cov-2 infection
AU2023227470A1 (en) 2022-03-02 2024-08-29 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
JP2025508942A (ja) 2022-03-02 2025-04-10 ギリアード サイエンシーズ, インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
KR20240155326A (ko) 2022-03-03 2024-10-28 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물 및 이의 제조와 사용 방법
EP4486747A1 (en) 2022-03-03 2025-01-08 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
JP2025519390A (ja) 2022-06-06 2025-06-26 ギリアード サイエンシーズ, インコーポレイテッド Sars-cov-2を含むウイルス感染の治療方法
EP4547334A1 (en) 2022-06-29 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
WO2024006461A1 (en) 2022-06-30 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4665737A1 (en) 2023-02-16 2025-12-24 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250084088A1 (en) 2023-08-31 2025-03-13 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2025054278A1 (en) 2023-09-06 2025-03-13 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
TW202517647A (zh) 2023-09-28 2025-05-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2826770T3 (en) 2005-06-24 2019-01-07 Biotron Ltd Acylguanidine compounds with antiviral activity
WO2009018609A1 (en) * 2007-08-03 2009-02-12 Biotrom Limited Hepatitis c antiviral compositions and methods
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
MX392650B (es) * 2014-07-07 2025-03-24 Elian Llc Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion
CN110870864B (zh) 2018-08-29 2021-09-24 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Also Published As

Publication number Publication date
WO2018145148A1 (en) 2018-08-16
ES2910136T3 (es) 2022-05-11
NZ755900A (en) 2025-03-28
MX2019009443A (es) 2019-12-16
CN110325187B (zh) 2022-09-30
US10918623B2 (en) 2021-02-16
EP3579833A4 (en) 2021-01-13
JP7019727B2 (ja) 2022-02-15
MX387115B (es) 2025-03-19
CA3052503A1 (en) 2018-08-16
US20200093796A1 (en) 2020-03-26
KR102607599B1 (ko) 2023-11-28
BR112019016316A2 (pt) 2020-03-31
SG11201907034PA (en) 2019-08-27
JP2020506243A (ja) 2020-02-27
RU2019126746A (ru) 2021-03-09
KR20190112051A (ko) 2019-10-02
RU2769317C2 (ru) 2022-03-30
EP3579833B1 (en) 2022-01-05
AU2018218179B2 (en) 2023-05-04
AU2018218179A1 (en) 2019-08-22
CN110325187A (zh) 2019-10-11
EP3579833A1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
BR122021024397A2 (enExample)
RU2019126746A3 (enExample)
BR122021000189A2 (enExample)
BR112020006084A8 (enExample)
BR112019008823A2 (enExample)
BR122022025811B8 (enExample)
BR202018014992U2 (enExample)
BR122021023687A2 (enExample)
BR122021014832A2 (enExample)
BR122022003518A2 (enExample)
BR112020008820A2 (enExample)
BR202017025154U2 (enExample)
BR102017023327A2 (enExample)
BR202017021228U2 (enExample)
BR202017020981U2 (enExample)
BR202017017068U2 (enExample)
BR202017016984U2 (enExample)
BR202017016924U2 (enExample)
BR102017015495A2 (enExample)
BR102017015250A2 (enExample)
BR102017014430A2 (enExample)
BR202017012548U2 (enExample)
BR202017011220U2 (enExample)
BR202017010814U2 (enExample)
BR202017010373U2 (enExample)